While preexisting T2DM might facilitate distant metastasis in small cell lung cancer (SCLC), it is the use of insulin therapy, not solely preexisting T2DM, that adversely impacts the prognosis of SCLC patients. This evidence concerns the gene INS and type 2 diabetes mellitus.